Financial Sector - The banking sector showed a general upward trend with notable performances from major banks such as China Life Insurance and Ping An Insurance, with market capitalizations of 380.77 billion and 1,023.96 billion respectively [4] - China Life Insurance experienced a slight decline of 0.29% while Ping An Insurance decreased by 0.58% [4] Semiconductor Sector - The semiconductor sector displayed mixed results, with North Huachuang's market capitalization at 241.30 billion and a decrease of 0.32% [4] - Cambrian's stock price increased slightly by 0.13%, while Haiguang Information saw a decline of 0.49% [4] Automotive Sector - The automotive sector, led by BYD with a market capitalization of 1,790.49 billion, experienced a minor decline of 0.31% [4] - Great Wall Motors and China Railway High-speed also showed slight increases of 0.41% and 1.05% respectively [4] Energy Sector - In the energy sector, China Petroleum and China Petrochemical had market capitalizations of 1,588.62 billion and 693.52 billion respectively, with China Petroleum increasing by 1.28% [4] - China Shipping Development remained stable with no change [4] Coal Industry - The coal industry saw Shaanxi Coal and China Shenhua with market capitalizations of 750.83 billion and 185.66 billion respectively [4] - China Shenhua's stock price increased by 4.03% while Shaanxi Coal remained unchanged [4] Food and Beverage Sector - The food and beverage sector included major players like Haitian Flavor Industry with a market capitalization of 228.10 billion, which increased by 0.46% [5] - Other companies in this sector showed stable performances with minor fluctuations [5] Electronics and Pharmaceuticals - The electronics sector, represented by Hon Hai Precision Industry, had a market capitalization of 365.78 billion and a slight increase of 0.34% [5] - In pharmaceuticals, Hengrui Medicine's market capitalization was 529.06 billion, with a notable increase of 0.99% [5] Logistics and Medical Devices - The logistics sector, led by SF Holding, had a market capitalization of 2,415.92 billion, experiencing a decline of 0.88% [5] - In medical devices, Mindray Medical's market capitalization was 172.94 billion, with a minor decrease of 0.02% [5] Metals and Construction - The non-ferrous metals sector included Zijin Mining with a market capitalization of 247.51 billion, which saw a decline of 3.38% [5] - China State Construction had a market capitalization of 1,700.78 billion, with a slight increase of 0.67% [5]

答：从数据来看，公司研发占比提升一方面是因为集采之后 公司整体营收下降；另一方面是公司在集采降价之后仍保持原有 的研发投入。公司研发投入处于上升阶段主要因为公司涉及产品 的品相较多，公司在创伤、脊柱、关节、运动医学这四大骨科领 域以及齿科、神经外科、微创外科等非骨科领域均有相应研发投 入。公司各产线的研发投入主要聚焦在材料、工艺及临床效果（如 缩短手术时间、减小创伤等）等方面。 5、问：公司未来几年还有什么重大的资本支出计划吗？ 证券代码：002901 证券简称：大博医疗 大博医疗科技股份有限公司投资者关系活动记录表 投资者关系活动 类别 ■特定对象调研（电话会） □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 国联民生证券、汇添富基金、兴证全球基金、宏利基金、福泽源 基金、工银瑞信、国泰海通证券、国联民生证券、大成基金、红 土创新基金、泽源资产、天风证券、华能贵诚信托、中金公司、 国信证券 时间 2025 年 7 月 8 日 (周二) 下午 15:30~16:30 地点 公司会议室 上市公司接待人 员姓名 董事长：林 ...

山外山 20250708 摘要 国内血液净化行业发展空间广阔，患者数量持续增长，但国产替代率仍 有提升空间，山外山和威高雪净等企业有望受益。 山外山在血液净化设备和耗材方面均具备优势，尤其与瑞士 Dialife 合资 的德莱福透析器，以蒸汽灭菌技术提升产品品质，具有市场竞争力。 山外山积极拓展海外市场，尤其在巴西、俄罗斯及东南亚等地销售增长 迅速，境外收入占比虽小但增速显著，未来有望成为重要增长点。 预计山外山未来三年收入和利润将保持 30%左右的复合增长率，设备销 售仍是主要收入来源，耗材和医疗服务业务稳步增长。 山外山管理团队稳定，创始人高光勇先生为实际控制人，具备核心技术 优势，多次参与国家技术标准制定，增强了公司在血液净化领域的竞争 力。 政策推动国产替代，集采降价对山外山出厂价影响较小，公司通过技术 创新和全线产品布局，提升市场竞争力，并积极发展血液透析服务。 综合考虑行业前景、产品竞争力、海外业务增长潜力及估值水平，认为 山外山具备长期投资价值，当前是观察并投资的良好时机。 Q&A 山外山在国内血液净化领域的地位如何？ 山外山是国内血液净化领域的龙头企业，无论是在设备还是耗材方面都具有领 先地位。 ...

转自：前瞻产业研究院 1、深圳市高端医疗器械产业政策环境 ——深圳市高端医疗器械产业重点政策梳理 深圳作为中国改革开放的标杆城市，其政策红利的持续释放与创新迭代，使其成为全球投资者不可忽视 的战略高地。深圳从"政策红利"向"产业红利"转型的核心抓手是科技创新，始终以产业需求为导向，推 动产业结构向高端化、智能化跃迁。 作为全球和中国高端医疗器械产业的核心阵地，深圳的政策红利的精准性、系统性和前瞻性，使其成为 资本与技术汇聚的"超级磁场"。 近年来，深圳市出台多项鼓励性政策，不断加大对高端医疗器械产业的支持力度。2024年3月，深圳出 台《关于加快发展新质生产力进一步推进战略性新兴产业集群和未来产业高质量发展的实施方案》，指 出针对具有战略意义、处于风口期、资源投入大的高端医疗器械等7个产业集群，举全市之力集聚资 源，以超常规力度支持培育。 | 时间 | 政策名称 | 内容解读 | | --- | --- | --- | | 2025年4月 | 《深圳市全链条支持医药 和医疗器械发展若干措 | 聚焦高端医学影像、医用机器人、高性能植介入器械、体外诊断、生命监护 | | | | 与支持、人工智能辅助诊断系统等方向 ...

Market Overview - The three major indices opened mixed, with the Shanghai Composite Index and Shenzhen Component Index both up by 0.04%, while the ChiNext Index opened down by 0.08% [1] - The Shanghai Composite Index is at 3,498.72 points, with a slight increase of 0.04% and a trading volume of 52.45 billion [2] - The Shenzhen Component Index is at 10,592.51 points, also up by 0.04%, with a trading volume of 81.21 billion [2] - The ChiNext Index is at 2,179.32 points, down by 0.08%, with a trading volume of 35.64 billion [2] External Market - The US stock market showed mixed results, with the Dow Jones down by 0.37% at 44,240.76 points, the S&P 500 down by 0.07% at 6,225.52 points, and the Nasdaq up by 0.03% at 20,418.46 points [3] - Chinese concept stocks performed well, with the Nasdaq China Golden Dragon Index up by 0.71%, outperforming the US indices [3] Industry Insights - CITIC Securities reports a positive long-term trend in the medical device industry, driven by innovation, mergers, and internationalization, with expectations of high growth in Q3 due to new product launches [4] - CICC anticipates continued high growth in new consumption sectors, particularly in health drinks and snacks, with a stable improvement in the food and beverage sector [5] - China Galaxy Securities highlights that leading companies in the steel industry are expected to benefit from improved supply-demand dynamics due to upcoming supply-side reforms [6] - CITIC Securities notes that the overseas energy storage and industrial storage sectors are at a turning point, with expectations of significant performance improvements for leading companies by Q2 2025 [7]

内容概要：随着中国经济的发展，人们的生活水平不断提高，更多的人开始重视健康和运动，他们会更 多地投入到健身运动中，这使得肌内效贴布的需求稳步上升。特别是在运动员和健身爱好者中，肌内效 贴布凭借透气性、舒适性、缓解疼痛、支持、放松软组织等优点，逐渐成为人们日常运动装备的一部 分。此外，随着老龄化速度的加快，越来越多的老年人开始关注肌内效贴布，尤其是在缓解关节和肌肉 疼痛方面，功能性贴布的需求不断增加，进一步推动肌内效贴布行业规模增长。据统计，2024年中国肌 内效贴布行业市场规模达到19.9亿元，同比上涨15.0%。 肌内效贴布是一种带有弹性的超薄透气胶带，有不同的宽度、颜色和弹性，可以根据需要剪切成不同的 形状，贴在需要治疗的皮肤、肌肉和关节上。与传统的膏药或药布相比，它极大减少皮肤过敏或适应不 良的情形，且允许治疗部位自然活动。肌内效贴布于20世纪70年代起源于日本，发展于欧美，而国内对 肌内效贴布的认识则始于北京奥运会。经推广，现该技术不仅用于各类运动损伤的处理，且广泛延伸到 临床康复等领域。目前，肌内效贴布主要有三个方面的治疗作用：①缓解疼痛；②改善循环，减轻水 肿；③支持、放松软组织，改善不正确的动作 ...

Core Viewpoint - China has implemented restrictions on medical device procurement from European companies in response to similar measures taken by the EU against Chinese firms, indicating a tit-for-tat approach in trade relations [1][5]. Group 1: Government Procurement Measures - The Ministry of Finance announced that for medical device procurement budgets exceeding 45 million RMB, EU companies will be excluded from participation, except for EU-funded enterprises operating in China [2][4]. - The measures specifically target 50 types of medical devices imported from the EU, including both everyday medical instruments and high-end equipment like MRI and X-ray diagnostic devices [4][6]. Group 2: Impact on Domestic Industry - The restrictions are expected to significantly impact high-end medical device manufacturers from the EU, while domestic companies are increasingly filling the market gap with competitive products [5][6]. - Currently, imported medical devices account for 40% of a typical domestic company's business, with only 10% coming from the EU, indicating a shift towards non-EU suppliers [4][6]. Group 3: Future Trends in Domestic Medical Device Market - The domestic medical device industry is projected to see an increase in the replacement rate of imported products, with estimates suggesting that 60% to 80% of devices priced around 5 million RMB can be sourced domestically [7][8]. - The market for high-end medical devices is expected to grow significantly, with projections indicating that by the end of the 14th Five-Year Plan, the market size could reach approximately 2.27 trillion RMB, accounting for 28% of the global market [8][9].

Core Viewpoint - Xiangsheng Medical (688358) announced a cash dividend distribution of 10 CNY per 10 shares, totaling 111,874,753 CNY, which represents 79.62% of the company's net profit attributable to shareholders for the year [1][2][4] Trading Information Summary - On July 8, 2025, Xiangsheng Medical's stock closed at 29.9 CNY, with a slight decline of 0.07%. The turnover rate was 0.93%, with a trading volume of 10,400 shares and a total transaction value of 31,227,400 CNY [1] - The fund flow on the same day showed a net outflow of 480,670 CNY from main funds, accounting for 15.39% of the total transaction value, while retail funds had a net inflow of 598,990 CNY, representing 19.18% of the total [1][4] Company Announcement Summary - Xiangsheng Medical's 2024 annual profit distribution plan includes a cash dividend of 10 CNY per 10 shares (before tax), with the base for distribution being 111,874,753 shares after deducting 249,784 shares held in the repurchase account [1][2] - The dividend distribution will not involve capital reserve conversion into share capital or the issuance of bonus shares. The record date for the dividend is July 14, 2025, and the ex-dividend date and payment date are both set for July 15, 2025 [1][2]

董秘最新回复 截至2025年7月8日收盘，美好医疗(301363)报收于18.17元，下跌0.27%，换手率5.0%，成交量7.81万 手，成交额1.41亿元。 投资者： 董秘您好，1、在2024年年报的行业发展趋势里提到产业技术加快，运用生物、微纳米、信 息、计算机、微加工等高新技术，发展用于微创或无创诊疗的技术和器件，表面改性和组织诱导性生物 医用材料及组织和器官修复器械，以及用于医院及远程诊疗的信息系统。请问贵司产品使用了当下哪些 新技术？2、医疗器械产品向智能化方向转变。请问贵司产品如何体现智能化的应用，比如是否使用机 器人、传感器等提高效率？ 董秘： 尊敬的投资者，您好！公司已预约于2025年8月19日披露2025年半年度报告。感谢您对公司的关 注！ 当日关注点 交易信息汇总：7月8日主力资金净流出706.11万元，而散户资金净流入591.99万元。 交易信息汇总 董秘： 尊敬的投资者，您好！技术应用方面。公司构建了基于通用技术模块化复用与专用技术纵深攻 关的开放式研发创新平台。一方面，基于长期服务全球医疗器械头部客户积累的技术基础，公司研发团 队将医疗器械组件及产品的开发技术、塑胶和液态硅胶精密模 ...

Core Points - The document outlines the procedures and regulations for the resignation of directors and senior management at Yingke Medical Technology Co., Ltd, aiming to maintain corporate governance stability and protect the rights of the company and its shareholders [1][2]. Chapter Summaries Chapter 1: General Provisions - The regulations are established based on relevant laws and the company's articles of association to standardize the resignation process of directors and senior management [1]. Chapter 2: Resignation Circumstances and Procedures - Directors can resign before their term ends by submitting a written resignation report, which becomes effective upon receipt by the company, and the company must disclose this within two trading days [2]. - If a director resigns and it results in the board falling below the legal minimum number of members, the director must continue to fulfill their duties until a new director is appointed [2]. - The company must complete the election of a new director within sixty days after a resignation to ensure compliance with legal and regulatory requirements [2]. - Senior management can also resign before their term ends, with specific procedures outlined in their labor contracts [2]. Chapter 3: Handover Procedures and Obligations - Resigning directors and senior management must complete handover procedures within five working days after their resignation, including transferring company seals and all relevant documents [3]. - If there are outstanding public commitments, the company can require a written fulfillment plan from the resigning personnel [3]. Chapter 4: Management of Shares Held by Resigning Directors and Senior Management - Resigning directors and senior management are prohibited from transferring their shares within six months of resignation [4]. - There are restrictions on the amount of shares that can be sold during their term and after resignation, ensuring compliance with relevant regulations [4]. Chapter 5: Accountability Mechanism - The board will review and determine accountability measures if a resigning director or senior management fails to fulfill commitments or obligations [5]. - Individuals can appeal the board's decisions regarding accountability within fifteen days [5]. Chapter 6: Supplementary Provisions - Any matters not covered by these regulations or conflicting with national laws will be governed by the relevant laws and the company's articles of association [6].